Standard Biotools Inc (LAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Standard Biotools Inc (LAB) has a cash flow conversion efficiency ratio of -0.019x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.31 Million) by net assets ($539.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Standard Biotools Inc (LAB) market capitalisation for the company's overall valuation and market capitalisation.
Standard Biotools Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Standard Biotools Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Standard Biotools Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Standard Biotools Inc ranked by their cash flow conversion efficiency. Explore LAB operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bait Bakfar Ltd
TA:BKFR
|
0.010x |
|
Lightron Inc.
KQ:069540
|
-0.041x |
|
LNA Sante SA
PA:LNA
|
0.084x |
|
Ingevec
SN:INGEVEC
|
0.045x |
|
Western New England Bancorp Inc
NASDAQ:WNEB
|
0.027x |
|
Compucase Enterprise Co Ltd
TW:3032
|
0.180x |
|
Dharma Polimetal Tbk PT
JK:DRMA
|
0.063x |
|
Keyfield International Berhad
KLSE:5321
|
0.117x |
Annual Cash Flow Conversion Efficiency for Standard Biotools Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of Standard Biotools Inc from 2006 to 2025. View LAB stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $424.29 Million | $-74.35 Million | -0.175x | +42.38% |
| 2024-12-31 | $471.72 Million | $-143.45 Million | -0.304x | -204.01% |
| 2023-12-31 | $-148.05 Million | $-43.29 Million | 0.292x | -73.35% |
| 2022-12-31 | $-81.47 Million | $-89.37 Million | 1.097x | +335.52% |
| 2021-12-31 | $94.60 Million | $-44.06 Million | -0.466x | -320.10% |
| 2020-12-31 | $139.05 Million | $-15.42 Million | -0.111x | +51.63% |
| 2019-12-31 | $153.61 Million | $-35.21 Million | -0.229x | +34.41% |
| 2018-12-31 | $72.12 Million | $-25.20 Million | -0.349x | +55.14% |
| 2017-12-31 | $30.93 Million | $-24.10 Million | -0.779x | -6.06% |
| 2016-12-31 | $53.23 Million | $-39.10 Million | -0.734x | -143.23% |
| 2015-12-31 | $114.90 Million | $-34.70 Million | -0.302x | -100.77% |
| 2014-12-31 | $150.42 Million | $-22.62 Million | -0.150x | -818.07% |
| 2013-12-31 | $97.12 Million | $-1.59 Million | -0.016x | +90.57% |
| 2012-12-31 | $100.66 Million | $-17.48 Million | -0.174x | +43.68% |
| 2011-12-31 | $56.90 Million | $-17.54 Million | -0.308x | -606.80% |
| 2010-12-31 | $-189.17 Million | $-11.51 Million | 0.061x | -45.87% |
| 2009-12-31 | $-173.62 Million | $-19.51 Million | 0.112x | -38.04% |
| 2008-12-31 | $-158.34 Million | $-28.72 Million | 0.181x | +8.64% |
| 2007-12-31 | $-130.33 Million | $-21.76 Million | 0.167x | -20.53% |
| 2006-12-31 | $-106.17 Million | $-22.31 Million | 0.210x | -- |
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consum… Read more